TRAVERE THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost, Current
TRAVERE THERAPEUTICS, INC. (TVTX) had Debt Securities, Available-for-sale, Amortized Cost, Current of $400.87 million as of 2021-09-30, per its 10-Q filed 2021-10-29.
Discontinued › Notes › Credit Losses
us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent · last filed 2021-10-29
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost, Current $400.87M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost, Current $439.41M.
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost, Current $372.40M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost, Current $276.11M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost, Current |
|---|---|
| 2021-09-30 | $400.87M 10-Q · filed 2021-10-29 |
| 2021-06-30 | $439.41M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $372.40M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $276.11M 10-Q · filed 2021-10-29 |
| 2020-09-30 | $254.66M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $218.60M 10-Q · filed 2020-07-31 |
| 2020-03-31 | $290.98M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $335.21M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |